Serum markers in HCL 71
majority of patients with untreated hairy cell leuke- mia and correlated well with the malignant cell count in the peripheral blood. Similar to serum sIL2R and sCD22, there was a good correlation with sCD307 level and response to therapy in the limited number of patients evaluated. In conclusion, soluble serum markers provide a
simple means to evaluate tumor response. Their levels reflect the total body burden of disease and thus provide not only a means to evaluate the peripheral blood disease burden but an assessment of the tissue component of the disease. Rising serum sIL2R levels identify patients at risk of hematologic relapse and provide an early warning sign of impending overt relapse. Other surface markers such as sCD22 and IRTA2/FcRH5 can also be used to assess tumor burden in the serum, but sIL2R remains the best marker for following classic hairy cell leukemia. It does not reflect disease burden in variant hairy cell leukemia where it is not expressed. In interpreting serum tumor markers, it is important to follow the trend rather than the absolute level of any single value, particularly with sIL2R, where other factors can influence its level.
Potential conflict of interest: A disclosure form provided by the author is available with the full text of this article at
www.informahealthcare.com/lal.
References
1. Ise T, Kreitman RJ, Pastan I, Nagata S. Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation- associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera. Clin Chem Lab Med 2006;44:594–602.
2. Matsushita K, Margulies I, Onda M, et al. Soluble CD22 as a tumormarker for hairy cell leukemia. Blood 2008;112:2272–2277.
3. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990;113:619–627.
4. Levine SJ. Mechanisms of soluble cytokine receptor genera- tion. J Immunol 2004;173:5343–5348.
5. Junghans RP, Waldmann TA. Metabolism of Tac (IL2Ral- pha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 1996;183:1587–1602.
6. Sheu BC, Hsu SM, Ho HN, et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001;61:237–242.
7. Chilosi M, Semenzato G, Cetto G, et al. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987;70:1530–1535.
8. Steis RG, Marcon L, Clark J, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988;71:1304–1309.
9. Smith JW, Longo DL, Urba WJ, et al. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood 1991;78:1664–1671.
10. Arun B, Curti BD, Longo DL, et al. Elevations in serum soluble interleukin-2 receptor levels predict relapse in patients with hairy cell leukemia. Cancer J Sci Am 2000;6:21–24.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122